– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human clinical trial expected to initiate in the second half of 2026 – – Preclinical data to be presented in an oral presentation at ENDO on June 15, 2026 – – Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – June 10, 2

Galmed Pharmaceuticals acquired Colospan in a $4.5 million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion. The deal calls for Colospan shareholders and SAFE (Simple Agreement for Future Equity) holders to get $2.5 million in cash and $2 million in common ordinary shares at the close, which is expected to be completed by the end of the second quarter this year, the company said in a June 8 press release. The sale has been

June 9, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical milestone achieved by its global partner, Formation Bio. Formation Bio announced the dosing of the first participant in a Phase 1, first-in-human clinical trial (BLKR201-101-HV) evaluating BLKR201 (originally designated as LNK01006). The study is a single ascending dose (SAD) and mult

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, F

Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. T

June 8, 2026 -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway. SLEIPNIR is a multi-arm Phase 2a clinical trial platform designed to evaluate investigational disease-modifying therapies in Parkinson's disease, with focus on brain penetration, biological ta

Incyte announced Monday an agreement to acquire Vega Therapeutics, a wholly-owned subsidiary of Star Therapeutics, for up to $2 billion, confirming rumours first reported by the Financial Times a day earlier. The deal — which includes $1.25 billion upfront — is focused on the investigational monoclonal antibody VGA039 for von Willebrand disease (VWD). "VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Incyte CEO Bill Meury, who took up the reins

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to codevelop a therapy called bexobrutideg that’s nearing late-stage testing. Roche will pay Nurix $700 million up front and, in return, will split U.S. rights to the drug while gaining full ownership elsewhere. Roche will also cover 60% of the development costs and hand Nurix royalties on non-U.S. sales. N

June 8, 2026 - Kye Pharmaceuticals Inc. ("Kye"), a Canadian-based specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, today announced that Dyanavel® XR (amphetamine extended-release) tablets are now available through pharmacies and wholesalers nationwide. Dyanavel® XR is authorized for sale in Canada for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and older, as well as in children age

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerl